Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Sarcoma 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Small Cell Lung Carcinoma 22Neoplasms 7Lung Neoplasms 5Sarcoma 4Ovarian Neoplasms 4Breast Neoplasms 4Sarcoma, Ewing 3Neuroendocrine Tumors 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Neoplasm Metastasis 2Mesothelioma 2Desmoplastic Small Round Cell Tumor 2Colorectal Neoplasms 2Advanced Solid Tumors 2Stomach Neoplasms 1Solid Tumors 1SCLC, Extensive Stage 1Recurrence 1Platinum-Resistant Lung Small Cell Carcinoma 1Pancreatic Neoplasms 1Neutropenia 1Mesothelioma, Malignant 1Major Advanced Solid Tumors Other Than Colorectal 1Leukemia 1Leiomyosarcoma 1Glioblastoma 1Gastrointestinal Malignancies 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Pemetrexed 39Cisplatin 33pembrolizumab 21Nivolumab 17Carboplatin 16Ipilimumab 13Gemcitabine 10Cyclophosphamide 9fludarabine 6durvalumab 6Bevacizumab 6Radiotherapy, Intensity-Modulated 4LMB-100 4Dexamethasone 4tremelimumab 3tazemetostat 3spartalizumab 3olaparib 3niraparib 3atezolizumab 3anetumab ravtansine 3amatuximab 3Vinorelbine 3Paclitaxel 3Imatinib Mesylate 3Cerebral Decortication 3tislelizumab 2sargramostim 2fludarabine phosphate 2defactinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Mesothelioma × PM 01183 × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT03213301 2021-07-14

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

Swiss Cancer Institute

Phase 2 Completed
42 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡